Samsung Biologics said Thursday that it has won the prestigious “CDMO Leadership Awards” for the 12th consecutive year, marking a first for a Korean company.

The CDMO Leadership Awards is a globally recognized event organized by Outsourced Pharma, a pharmaceutical industry research institution, in collaboration with Life Science Connect, a life sciences media outlet.

The award is highly regarded in the industry as it is based on evaluations from actual client companies that have partnered with the CDMO firms.

Starting this year, the awards have been divided into specific portfolio categories, such as biologics and cell & gene Therapy, and companies are further classified based on their production facilities and research center locations into Global, International, and North America categories.

Samsung Biologics was awarded in the Biologics-Global category.

“Winning the CDMO Leadership Awards for 12 consecutive years is a testament to the strong trust our clients place in us,” Samsung Biologics CEO John Rim said. “We will continue to expand our production capabilities to supply high-quality biopharmaceuticals and maximize customer satisfaction through innovative technology and services.”

Meanwhile, Samsung Biologics has been achieving record-breaking performance annually, maintaining strong growth momentum. Last year, the company became the first in Korea’s biopharmaceutical industry to surpass 4.5 trillion won ($3 billion) in annual revenue, while its cumulative contract manufacturing orders exceeded 5 trillion won.